Description

Haemonetics’ Strategic Reset — Plasma, BMT & Cash Flow Drive Higher 2027 Guidance!

Haemonetics Corporation reported first quarter fiscal year 2027 results demonstrating continued profitable growth, with revenues totaling $339 million, reflecting a 6% increase both on a reported and organic basis. Adjusted earnings per diluted share rose 4% to $1.14. The company operates through three core platforms—Plasma, Blood Management Technologies (BMT), and Interventional Technologies (IVT)—all of which contributed positively to the quarter’s performance. The Medical-Surgical (MedSurg) segment achieved 6% year-over-year revenue growth supported by all franchises. BMT saw an 8% organic increase, highlighted by mid-teens disposable growth in Hemostasis Management, driven by strong product utilization and share gains, alongside steady progress in Transfusion Management’s software implementations that enhance recurring revenue streams. IVT posted 3% organic growth, led by a low-double-digit rise in Vascular Closure sales, underpinned by increased procedural volumes, strengthened commercial execution, and expanded product indications, particularly for the VASCADE MVP XL device.